It has been unclear to date as to whether the risk of death outweighs the risk of AVR-related death in asymptomatic AS patients, and the ESC2017 guidelines currently recommend watchful observance. However, there has never been a randomised trial to support this approach. Prof. Duk-Hyun Kang (Asan Medical Center, South Korea) presented the 8-year follow-up results of The Randomized Comparison of Early Surgery versus Conventional Treatment in Very Severe Aortic Stenosis (RECOVERY) study. RECOVERY was a prospective, multicentre, open-label, randomised trial in which asymptomatic patients with severe AS were randomly assigned to early surgery (n=73) or to conventional treatment (n=72). The primary endpoint of the trial was a composite of peri-operative mortality or cardiovascular death. The major secondary endpoint was death from any cause.
Patients randomised to early surgery received AVR within 2 months (n=69 intention-to-treat), while patients in the conventional treatment arm were treated according to the current guidelines (n=52 intention-to-treat). Patients who were assigned to conventional care were referred for AVR if they became symptomatic, had a left ventricle ejection fraction <0.50, or an increase in peak aortic velocity >0.5 m/s per year.
In the pre-emptive surgery group, the rate of peri-operative death was 1.4% at both 4 and 8 years of follow-up compared with 5.7% at 4 years and 25.5% at 8 years in the conventional treatment arm (P=0.003; see Figure). The rate of all-cause mortality was also higher in the conventional treatment arm compared with the early surgery group (9.7% vs 4.1% at 4 years and 31.8% vs 10.2% at 8 years, respectively; P=0.018; see Figure). The evidence from this trial strongly supports early AVR intervention for asymptomatic patients with severe aortic stenosis.
Figure: Primary and secondary endpoints of the RECOVERY trial [1]
1. Kang D-H, et al. RECOVERY: Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis. LBS04, AHA Scientific Sessions 2019, 14-18 November, Philadelphia, USA.
Posted on
Previous Article
« ISCHEMIA trial: Invasive treatment only better for angina burden Next Article
New guidelines on the prevention of cardiovascular conditions »
« ISCHEMIA trial: Invasive treatment only better for angina burden Next Article
New guidelines on the prevention of cardiovascular conditions »
Table of Contents: AHA 2019
Featured articles
New Approaches to CVD Risk Reduction
Phase 3 BETonMACE trial did not meet its primary endpoint
Inclisiran safely halves LDL-Cholesterol
Colchicine prevents cardiovascular events
Interventional Management for Acute Coronary Syndrome
Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy
Immediate coronary angiography after cardiac arrest does not improve survival
Complete revascularisation for obstructive non-culprit lesions with vulnerable plaque
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI
Intra-aortic balloon pump better than Impella: new observational data
Results for the Ischemia Trials: To Intervene or Not to Intervene
ISCHEMIA trial: Invasive treatment only better for angina burden
Controversies in Contemporary Management of Aortic Stenosis
Full GALILEO results: Why did rivaroxaban fail after TAVR?
Balloon-expandable better than self-expanding transcatheter heart valves
RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis
Guidelines: Updates and Controversies
New guidelines on the prevention of cardiovascular conditions
Trials in Electrophysiology and Left Ventricular Function
RENAL-AF trial: Apixaban similar to warfarin
Apple Heart Study: Not just for atrial fibrillation
Early apixaban safe as secondary prevention of stroke from AF
Carvedilol does not improve exercise performance in Fontan patients
New Frontiers in Lipid Therapy
Icosapent ethyl plus statins reduces total plaque volume
ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients
New RNAi therapies to reduce triglycerides: 2 studies show favourable results
Targeting LDL-C <70 mg/dL is better than 100 mg/dL after stroke
Challenges in Heart Failure Management
FUEL trial: Udenafil improves some exercise measurements in Fontan
DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
PARAGON-HF: Benefits for women and lower ejection fraction
Related Articles
February 26, 2020
Full GALILEO results: Why did rivaroxaban fail after TAVR?
February 26, 2020
Phase 3 BETonMACE trial did not meet its primary endpoint
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com